8-K
filed June 22, 2023, 7:59 PM ET
ticker CLSDQ
CIK 0001539029
other material
confidence high
sentiment neutral
materiality 0.10
Clearside Biomedical shareholders re-elect all three director nominees
Clearside Biomedical, Inc.
- Jeffrey L. Edwards, Clay B. Thorp, and Benjamin R. Yerxa re-elected with 21.0M, 21.0M, and 22.8M votes for, respectively.
- Advisory vote on executive compensation passed with 21.9M for, 1.0M against, 2.3M abstain.
- Ratification of Ernst & Young as auditor for FY 2023 approved (40.2M for, 0.1M against).
- Turnout: 40.7M shares (65.98%) of 61.7M outstanding present or represented.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Clearside Biomedical, Inc. shareholders approved Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-06-22 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-22
Exact text from the filing
Proposal No. 1 : Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Jeffrey L. Edwards 21,010,493 4,195,234 Clay B. Thorp 21,038,323 4,167,404 Benjamin R. Yerxa 22,824,670 2,381,057 Broker Non-Votes: 15,481,349. All nominees were elected.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Clearside Biomedical, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-22 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-22
Exact text from the filing
Proposal No. 3 : Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 40,223,369 118,934 344,773
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Clearside Biomedical, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement. at the 2023-06-22 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-22
Exact text from the filing
Proposal No. 2 : Approval, on an advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the compensation paid to the named executive officers 21,869,683 1,039,147 2,296,897 Broker Non-Votes: 15,481,349.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.